Abstract
We investigated the potential of intravenous lidocaine to reduce pain on awakening in a dose- dependent manner and aimed to determine the median effective dose of lidocaine in 200 children aged 3–12 years (American Society of Anesthesiologists physical status I–II) who underwent elective tonsillectomy with or without adenoidectomy at Yichang Central People’s Hospital. The patients were randomized into four dose groups (A–D: 0.0, 1.0, 1.5, and 2.0 mg/kg, respectively), and they underwent the same anesthetic induction and maintenance protocols. The primary outcome was pain on awakening, while secondary outcomes included pain scores at 1, 4, 12, and 24 h after awakening; incidences of laryngospasm, bronchospasm, or perioperative stridor; and time to extubation. Intraoperative cardiac events were classified as safety events. Our findings indicated that intravenous lidocaine dose-dependently reduced pain on awakening, with the median effective dose being 1.75 mg/kg. Significant differences were observed between groups A and D (P ≤ 0.001). No incidents of laryngospasm, bronchospasm, or perioperative stridor were observed. Furthermore, there were significant between-group differences in time to extubation (P ≤ 0.05). In conclusion, our study demonstrated that lidocaine dose-dependently reduced pain on awakening in children undergoing tonsillectomy with or without adenoidectomy, with no severe adverse events.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Chinese Clinical Trial Registry (http://chictr.org.cn/showproj.aspx?proj=136605) (registration number: ChiCTR2100053006
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study design was approved by the Institutional Review Board (president, Ke-Jun Yan) of Yichang Central People’s Hospital (approval number: HEC-KYJJ-2020-038-02 approval date: September 17, 2021). Written informed consent was obtained from the parents or guardians of all children enrolled in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available from the Ethics Committee (contact via corresponding author) for researchers who meet the criteria for access to confidential data.
